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Abstract
BACKGROUND: Encapsulated follicular tumours with equivocal papillary thyroid
carcinoma (PTC) type nuclear features continue to remain a challenge despite the
recent attempts to classify these borderline lesions. The term 'well differentiated
tumour of uncertain malignant potential (WDT-UMP)' was introduced to classify
these tumours. The present study aimed to evaluate the role of a cell cycle
regulator like cyclin D1 in these tumours along with assessment of other well
established PTC markers like galectin-3, HBME-1, CK19. METHODS: Thirteen
cases of metastatic PTC, papillary microcarcinoma and follicular variant of PTC
(FVPTC) were identified from a histological review of 510 cases. In addition, 13
cases of a subset of follicular adenomatoid nodules with focal areas showing
nuclear features characteristic of PTC, identified as WDT-UMP, were also
analyzed. Immunohistochemical analysis of galectin-3, HBME-1, CK19 and the
proliferation markers Ki67 and cyclin D1 was performed. Lesions w...
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Abstract
Background: Encapsulated follicular tumours with equivocal papillary thyroid carcinoma (PTC) type nuclear features
continue to remain a challenge despite the recent attempts to classify these borderline lesions. The term ‘well
differentiated tumour of uncertain malignant potential (WDT-UMP)’ was introduced to classify these tumours.
The present study aimed to evaluate the role of a cell cycle regulator like cyclin D1 in these tumours along with
assessment of other well established PTC markers like galectin-3, HBME-1, CK19.
Methods: Thirteen cases of metastatic PTC, papillary microcarcinoma and follicular variant of PTC (FVPTC) were
identified from a histological review of 510 cases. In addition, 13 cases of a subset of follicular adenomatoid
nodules with focal areas showing nuclear features characteristic of PTC, identified as WDT-UMP, were also analyzed.
Immunohistochemical analysis of galectin-3, HBME-1, CK19 and the proliferation markers Ki67 and cyclin D1 was
performed. Lesions were analyzed for cyclin D1 gene amplification by fluorescent in-situ hybridization.
Results: All WDT-UMP lesions showed immunolabelling of cyclin D1, Ki67; 11/ 13 cases showed immunolabelling of
CK19; 10/13 cases showed immunolabelling of HBME-1 and 4/13 cases showed immunolabelling of galectin-3.
Surrounding benign adenomatoid areas showed no to faint focal staining in all thirteen cases of cyclin D1, HBME-1
and galectin-3. A low rate of cyclin D1 gene amplification was identified in a significant proportion of cells in the
WDT-UMP lesions as compared to surrounding benign adenomatoid areas.
Conclusions: Increased expression of cyclin D1 and amplification of its gene along with immunolabelling of HBME-1
in WDT-UMP lesions showing cytological features of papillary thyroid carcinoma within follicular adenomatoid nodules
suggest that these areas could correspond to a precursor lesion of follicular variant of PTC. Overexpression of cyclin D1,
associated with the amplification of the gene suggests that these WDT-UMP lesions are an intermediate between the
benign and malignant groups making this group of lesions a reliable precursor of FVPTC.
Virtual slides: The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/
1851820807142117
Keywords: Thyroid, Papillary carcinoma, Follicular variant of papillary carcinoma, WDT-UMP, Follicular adenomatoid
nodule
Background
Papillary thyroid carcinoma (PTC) is the commonest
endocrine malignancy. It constitutes 85-90% of all
thyroid malignancies [1]. In USA and Belgium, PTC
has shown the most rapid increase in incidence
among all malignancies among women [1,2]. Among men,
PTC is the malignancy with the second-fastest increase in
incidence [3]. Despite the progress in understanding PTC,
diagnostic difficulties and inter-observer variability is seen
in encapsulated follicular lesions showing nuclear changes
of PTC without definite invasion.
Encapsulated follicular lesions, namely follicular
adenoma/adenomatous nodule, follicular variant of
PTC (FVPTC), and follicular thyroid carcinoma have
always been the bane of the histopathologist [4].
Morphologically, PTC-nuclear changes such as nuclear
clearing, nuclear grooves, enlargement and overlapping
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along with cytoplasmic pseudoinclusions are the diagnostic
criteria of malignancy in a thyroid tumour irrespective of
the growth pattern of the tumour or its aggressiveness [5].
However, when PTC-nuclear changes are ambiguous and
there is no capsular/ blood vessel invasion in an encapsu-
lated tumour, a new diagnostic term “well differentiated
tumour of uncertain malignant potential (WDT-UMP)” has
been introduced to describe this problematic entity [6],
although there is no direct proof of its borderline malignant
nature yet [7,8]. A review of cases of PTC led us to a
particular diagnostic dilemma in a subset of follicular ade-
nomatoid nodules with nuclear features partially character-
istic of PTC (i.e., focal nuclear clearing, occasional nuclear
grooves, nuclear enlargement, angulated nuclear contours
and overlapping nuclei) but the histologic features did not
display classic malignant characteristics (Figure 1). We de-
cided to interrogate this controversial entity to determine
its intermediate nature in progression to a malignant lesion.
In recent years, quite a few immunohistochemical
markers have been implicated to identify PTC and also to
distinguish it from benign mimics. The most promising
and widely used ones are galectin-3, Hector Battifora
Mesothelial cell (HBME)-1, and cytokeratin (CK) 19 [9].
Galectin-3 is involved in cell adhesion, growth and differen-
tiation in multiple tissues [10]. CK19 shows a strong diffuse
cytoplasmic immunoreactivity in PTC whereas HBME-1 is
useful in the diagnosis of malignant tumours of follicular
epithelial derivation [9,10]. PTCs show increased prolifera-
tion compared to normal thyroid tissue or benign lesions,
when assessed with Ki67, a well characterized proliferation
marker [11,12]. Cell cycle progression is brought about by
cyclin-dependent kinases (CDKs) that are activated by
cyclins including cyclin D1 and inactivated by CDK
inhibitors. Cyclin D1 proto-oncogene regulates G1 to
S-phase transition in cell cycle in different tissues [11,13].
Overexpression of cyclin D1, associated with the amplifica-
tion of the CCND1 gene, has been reported in oesophageal,
lung, breast and head and neck carcinomas [14,15].
In this analysis, we used galectin-3, HBME-1, CK19, Ki67
and cyclin D1 to evaluate the borderline nature of this
tumour. Identification of a biomarker that is consistently
present in invasive as well as precursor lesion and absent in
the adjacent normal thyroid tissue will provide evidence
Figure 1 The WDT-UMP lesion, follicular variant of papillary carcinoma developing in a follicular adenomatoid nodule. Left panel, low power view
with the WDT-UMP lesion at left; right panel, high magnification of the WDT-UMP lesion (H&E; bar = 200 μm).
Table 1 Clones of the antibodies used in the study
Antibody Clone Dilution Manufacturing company
Galectin-3 9C4 1:200 Novocastra, Newcastle, UK
HBME-1 HBME-1 1:50 DakoCytomation, Glostrup, Denmark
CK19 b-170 1:200 Novocastra, Newcastle, UK
Cyclin D1 SP 4 1:25 Thermo Scientific, Fremont, CA, USA
Ki67 MIB 1 1:100 DakoCytomation, Glostrup, Denmark
Table 2 General findings and follow up of the WDT-UMP
lesion group
S.
No
Age at
presentation
Sex Presenting
complaints
Diagnosis
since
Prognosis
1 63 years M Nodular goitre 10 years No recurrence
2 56 years F Nodular goitre 5 years No recurrence
3 55 years F Nodular goitre 5 years No recurrence
4 57 years F Nodular goitre 10 years No recurrence
5 50 years F Nodule with
dysphonia
3 years No recurrence
6 50 years F Multinodular
goitre
13 years No recurrence
7 39 years F Multinodular
goitre
3 years No recurrence
8 37 years M Mutinodular
goitre
5 years No recurrence
9 36 years F Nodule with
hepatitis C
9 years No recurrence
10 34 years F Multinodular
goitre
13 years Lost to follow up
11 27 years F Nodular goitre 11 years No recurrence
12 17 years F Nodular goitre 7 years No recurrence
13 13 years F Nodular goitre 6 years No recurrence
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that this group of lesions is a reliable precursor of follicular
variant of PTC (FVPTC).
Methods
Patients and selection of cases
Thirteen follicular adenomatoid nodules with focal areas
showing PTC-nuclear changes were selected as WDT-UMP
after a review of cases (1990 till date) done jointly by three
authors (MLS, BW, and JR). The selection of the cases was
made according to the WDT-UMP criteria described by
Williams et al. [6]. The tumours were encapsulated with
focal areas showing nuclear features of PTC like clearing,
enlargement, grooves, angulated contours and overlapping
(Figure 1). Papillary microcarcinoma and infiltrative meta-
static PTC were selected as control groups according to the
criteria of the World Health Organization [16]. FVPTC was
selected by the criteria described by LiVolsi et al. [17]. Since
only thirteen cases of the WDT-UMP lesion were available,
we selected thirteen cases of several categories of PTC,
including papillary microcarcinoma, FVPTC and meta-
static PTC, and compared them to the thirteen cases of
WDT-UMP lesion. The study was approved by the Ethics
Committee of the Université catholique de Louvain.
Immunohistochemistry
Formalin-fixed paraffin-embedded 5-μm-thick sections
were deparaffinised and rehydrated. Endogenous peroxidase
activity was blocked with 3% hydrogen peroxide. Antigen
retrieval was performed in 0.01 M citrate buffer (pH 5.8)
inside a boiling water bath for 75 min followed by
incubation in 0.05% Triton X-100, 0.05 M Tris–HCl,
pH 7.4 containing 10% goat serum to block non-specific
binding. Primary antibody incubation (Table 1) was
carried out overnight at room temperature. Slides
were incubated with DAKO EnVision + System™, HRP
for 60 minutes and the reaction visualized using 3,
3′-diaminobenzidine tetrahydrochloride (DAB). Controls
were incubated with 0.05 M Tris–HCl, pH 7.4 containing
1% goat serum in place of the primary antibody, and no
staining was observed. The adjacent normal thyroid tissue
was used as an internal control for immunolabelling.
Evaluation of immunostaining
Digitalization of the scanned slides was done at a 20x
magnification by SCN400 slide scanner (Leica, Wetzlar,
Germany). Scanned slides were analyzed using Tissue IA
(Leica Biosystems, Dublin, Ireland). The tumour tissue
was delineated manually and folds, bubbles and dirties
were excluded from the analysis. Colour deconvolution
was applied using hematoxylin and DAB matrices of the
software. Nuclear algorithms were applied for cyclin
D1 and Ki67 immunostaining, keeping the parameters
constant for all slides. Thresholds were adjusted for tissue
and DAB detection and also for nuclear segmentation.
Percentage of nuclei with positive staining and corre-
sponding staining intensity were generated. Cyclin D1
immunoreactivity was evaluated as: negative; grade 1,
focal staining in less than 25% of tumour cells; grade
2, staining in 25–50% of tumour cells; and grade 3,
diffuse staining in more than 50% of tumour cells
Figure 2 Immunolabelling of the WDT-UMP lesion for galectin-3 (2a), HBME-1 (2b), and CK19 (2c) with the corresponding adenomatoid
nodule (bar = 200 μm).
Table 3 Galectin-3, HBME-1 and CK19 immunolabelling in
the variants of PTC
Variant FVPTC WDT-UMP
lesion
Papillary
microCa
Metastatic
papillary Ca
Galectin-3 08/13 04/13 09/13 13/13
HBME-1 10/13 10/13 12/13 13/13
CK19 11/13 11/13 11/13 13/13
Table 4 Ki67 immunolabelling in the variants of PTC
Variants of PTC Percentage of Ki67 immunolabelled
tumour cells
No
staining
Grade 1
(<1%)
Grade 2
(1–5%)
Grade 3
(6-20%)
FVPTC (n = 13) 1 3 3 6
WDT-UMP lesion (n = 13) 0 2 6 5
Papillary microCa (n = 13) 2 3 6 2
Metastatic papillary Ca (n = 13) 0 0 2 11
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[18]. Ki67 staining was scored according to percentage of
cells showing nuclear staining, as less than 1%, 1 to 5%,
and 5 to 20% [18].
For CK19 and HBME-1, a distinct staining in cyto-
plasm and cell membranes was considered as significant.
Galectin-3 showed nuclear and cytoplasmic staining in
thyroid carcinomas. The staining in the normal thyroid
tissue surrounding the follicular adenomatoid nodules
was also evaluated at the same time as the tumour.
Fluorescent in-situ hybridization
Testing for cyclin D1 gene amplification was done using the
Vysis CCND1/CEP 11 kit (Abbott SA, Louvain-la-Neuve,
Belgium), including probes for cyclin D1 gene (11q13,
spectrum orange) and chromosome 11 (11p11.11q11,
spectrum green). Briefly, the 4 μm-thick sections were
deparaffinised, rehydrated and placed in a HCl bath (0.2 N,
10 min, room temperature). Slides were immersed in
0.01 M citrate buffer (pH 6.1) inside a water bath
(20 min, 100°C) and then treated with Tissue digest
(Insitus Biotechnologies, Albuquerque, NM, USA) for
85 minutes at 38°C to unmask target DNA sequences
followed by sequential washing with deionised water
and 2X SSC solution. Probes (10 μl) were added to
each slide and denaturation was performed by placing the
slides on a hot plate (90°C, 13 min). Hybridization was
carried out in a prewarmed humidified box kept in a 37°C
incubator for 16 hours. Post-hybridization wash was done
and nuclei were counterstained with 4′, 6-diamidino-2-
phenylindole and signals from 200 nuclei were counted
under a fluorescent microscope (Zeiss, Axioplan 2).
Statistical analysis
Computations were performed using GraphPad Prism
version 5.04 for Windows [19]. One-way ANOVA
test was employed to look for significant difference
in the immunolabelling of Ki67 and cyclin D1.
Tukey’s post hoc test was done in cases of signifi-
cance. Paired t-test was done to determine a differ-
ence in cyclin D1 gene amplification by FISH in
different PTC variants and the surrounding normal
thyroid tissue or benign adenomatoid areas. Galectin-
3, HBME-1 and CK19 staining in the adenomatoid
and neoplastic areas were analysed with a chi-square
test. Statistical significance was defined at the level
of p < 0.05 (two-tailed test).
Results
The clinical details of the WDT-UMP cases are summarised
in Table 2. Eleven out of thirteen patients were females,
effectively drawing a male:female ratio of 1:5.5. The average
age at presentation was 37 ± 18 (mean ± SD) years, the
oldest being 63 years and the youngest being 13 years.
Twelve out of 13 patients were available for follow-up for a
period ranging from 36 to 132 months (average 74 months).
None of them showed recurrence of the disease. Focal areas
Figure 3 Ki67 immunolabelling in the WDT-UMP lesion, FVPC in FA (3a), papillary microcarcinoma (3b), FVPC (3c) and metastatic PTC
(3d) (bar = 200 μm).
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of WDT–UMP areas inside the follicular adenomatous
nodule ranged in size from 3 mm to 1 cm. The WDT-UMP
areas had thyroid follicles lined by cuboidal epithe-
lium and showed relatively less colloid compared to
the surrounding adenomatous areas. The nuclei were
enlarged 2 to 4 times compared to that of the normal
thyroid follicular cells and showed clearing, angulated
contours, grooves and occasional nuclear overlapping
and cytoplasmic pseudoinclusions.
Immunohistochemical results
All cases of metastatic PTC showed immunolabelling for
HBME-1, CK19 and galectin-3. Galectin-3 was expressed
in FVPTC (61%), papillary microcarcinomas (69%), and
only in 30% cases of the WDT-UMP (Figure 2a). It
showed no immunostaining in normal and adenomatoid
areas. Membranous staining of HBME-1 was seen in
FVPTC (76%), papillary microcarcinomas (92%) and
WDT-UMP (76%) (Figure 2b). No immunostaining was
found in the adjacent normal thyroid tissue. A non
specific weak reactivity for HBME-1 was present at the
luminal surface of some follicular cells in adenomatoid
areas. CK19 showed diffuse cytoplasmic staining in
FVPTC (84%), papillary microcarcinomas (84%), and
WDT-UMP (84%) (Figure 2c, Table 3). The normal areas
were unreactive for CK19; however, 80% of benign ade-
nomatoid areas showed focal weak staining for CK19. The
chi-square test showed significant difference of galectin-3
and HBME-1 staining between WDT-UMP and the sur-
rounding adenomatoid areas (p < 0.05).
Proliferation as assessed by Ki67 staining revealed low
scores in these slow growing lesions (Table 4, Figure 3).
Figure 4 Cyclin D1 immunolabelling in the WDT-UMP lesion, FVPC in FA (4a), papillary microcarcinoma (4b), FVPC (4c) and metastatic PTC
(4d) (bar = 200 μm).
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Ki67 was not detected in normal thyroid tissue, which also
served as a control. A few cells were labelled in the benign
follicular adenomas but the proportion of immunolabelled
cells increased in the PTC variants. A one way ANOVA
test showed significant difference between all the lesions
(p < 0.01). Post hoc comparisons indicated that the mean
score for the metastatic PTC was significantly different
from benign follicular adenomatoid areas, WDT-UMP
and papillary microcarcinoma at p < 0.01.
Seven cases (54%) of WDT-UMP showed intense
grade 3 cyclin D1 nuclear staining; three cases (23%)
showed grade 2 staining and three cases (23%) showed
grade 1 focal nuclear staining. The corresponding
adenomatoid areas depict absent to faint focal nuclear
staining (Figure 4a). Twelve out of 13 FVPTC showed
nuclear staining of cyclin D1 with 6 (43%) showing
grade 3 diffuse staining. (Figure 4c, Table 5). Eleven
out of 13 papillary microcarcinomas showed nuclear
staining of cyclin D1 (Figure 4b) with grade 3 diffuse
nuclear staining seen in 5 (38%) of the tumours. All
the metastatic carcinomas showed nuclear cyclin D1
immunolabelling with 69% depicting intense, grade 3
diffuse nuclear staining (Figure 4d). No immunolabelling
was seen in normal thyroid tissue. There was no significant
difference in the immunolabelling between the different
variants according to ANOVA test. However, cyclin D1
immunolabelling in the WDT-UMP was significantly
different from the surrounding benign adenomatoid
areas (p = 0.012, using paired t test).
FISH results
A low rate of cyclin D1 gene amplification was found in
all the variants of PTC, metastatic PTC (19 ± 8% of cells),
FVPTC (13 ± 4%), papillary microcarcinoma (12 ± 6%) and
WDT-UMP (12 ± 5%). Ratio of CCND 1/CEP11 amplifi-
cation ranged from 1.5 to 2.5 (Figure 5). Cyclin D1 ampli-
fication was significantly higher in each PTC variant than
in normal tissue (p < 0.001) and in WDT-UMP than in
surrounding adenomatoid areas (p = 0.002).
Discussion
Immunohistochemical studies on thyroid borderline
lesions such as WDT-UMP have always focused on
the panel of well recognised markers like galectin-3,
HBME-1 and CK19 [5,20]. The recognition of WDT-UMP
using cyclin D1 as a marker is a first as per the available
English literature. We found significant cyclin D1 amplifi-
cation and intense nuclear cyclin D1 immunostaining in
the WDT-UMP lesion as compared to normal tissue
and adenomatoid areas. Increased proliferation was
also detected by Ki67 immunostaining.
Most cases of PTC variants and the WDT-UMP lesion
showed immunolabelling of HBME-1. Galectin-3 was
immunolabelled in only 30% of the WDT-UMP lesion
compared to 70-100% of PTC variants. CK19 was immu-
nolabelled in most cases of PTC variants and in the
WDT-UMP lesion but a weak immunostaining was also
detected in the surrounding benign adenomatoid areas.
Several investigators have reported CK19 immunostaining
of benign thyroid lesions as observed in the present study
[9,20]. Nasr et al. [20] have proposed that a lack of CK19
immunolabelling completely rules out PTC.
The idea of tumorigenesis in thyroid beginning from
chromatin clearing with nuclear atypia, followed by
appearance of nuclear grooves and pseudoinclusions,
and then developing into a FVPTC running the entire
gamut of changes from non-neoplastic disease to follicular
adenoma and then to carcinoma has been suggested by
Pennelli et al. [21]. We propose that follicular lesions with
equivocal nuclear features are indeed a precursor of
FVPTC wherein a progressive transformation to a malig-
nant phenotype takes place as determined by cyclin D1.
Figure 5 Amplification of cyclin D1 gene seen in the WDT-UMP le-
sion, FVPC in FA using FISH. Cyclin D1 gene appears in red whereas
chromosome 11 centromeric repeat region is green (bar = 20 μm).
Table 5 Cyclin D1 immunolabelling in the variants of PTC
Variants of PTC Percentage of cyclin D1
immunolabelled tumour cells
No
staining
Grade 1
(<25%)
Grade 2
(25-50%)
Grade 3
(>50%)
FVPTC (n = 13) 1 4 2 6
WDT-UMP lesion (n = 13) 0 3 3 7
Papillary microCa (n = 13) 2 4 2 5
Metastatic papillary Ca
(n = 13)
0 2 2 9
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Cyclin D1 regulates G1 to S phase progression and its
overexpression has been reported in various carcinomas
[14,15,22]. Cyclin D1 was identified as a strong candidate
diagnostic marker for PTC and its variants, particularly
the WDT-UMP lesion. No statistical difference was
observed between WDT-UMP and other variants of
PTC for the frequency of cyclin D1 immunolabelling.
However, cyclin D1 immunolabelling in the WDT-UMP
was significantly different from the surrounding benign
adenomatoid areas. HBME-1 and galectin-3 were not
labelled in the normal thyroid tissue or the benign
adenomatoid areas but were labelled in the WDT-UMP
lesions, strongly supporting the hypothesis. However,
neither of the cases in our study had invasion or cervical
lymphadenopathy at surgery, nor recurrence at follow-up.
Other studies have also reported a rather uneventful
follow-up of WDT-UMP lesions [23].
Conclusions
Increased expression of cyclin D1 and amplification of
its gene along with immunolabelling of HBME-1 in
WDT-UMP areas showing cytological features of PTC
within follicular adenomatoid nodules suggest that these
areas could correspond to a precursor lesion of follicular
variant of papillary thyroid carcinoma. Since there is a
significant overexpression of cyclin D1 in PTC and its
variants, we also advocate that antibodies against cyclin
D1 should be included in the immunohistochemical panel
as a diagnostic marker for PTC.
Take home message
 Cyclin D1 was identified as a strong candidate
diagnostic marker for PTC and its variants,
including papillary microcarcinomas and also the
WDT-UMP lesion. The recognition of WDT-UMP
using cyclin D1 as a marker is a first as per the
available English literature.
 HBME-1 was immunolabelled at the membrane in
most cases of the PTC variants and also in the
WDT-UMP lesion but not in the normal thyroid
tissue or the benign adenomatoid areas.
 Identification of a biomarker that is consistently
present in invasive as well as the WDT-UMP lesion
and absent in the adjacent normal thyroid tissue
provides evidence that this group of lesions is a
reliable precursor of FVPTC. Increased expression
of cyclin D1 and amplification of its gene along
with immunolabelling of HBME-1 in WDT-UMP
areas showing cytological features of papillary
thyroid carcinoma within follicular adenomatoid
nodules suggest that these areas could correspond
to a precursor lesion of follicular variant of papillary
thyroid carcinoma.
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